DE60332975D1 - Verwendung von Ranolazin zur Herstellung eines Medikaments zur Behandlung von frühen Nachdepolarisationen (EADs) - Google Patents

Verwendung von Ranolazin zur Herstellung eines Medikaments zur Behandlung von frühen Nachdepolarisationen (EADs)

Info

Publication number
DE60332975D1
DE60332975D1 DE60332975T DE60332975T DE60332975D1 DE 60332975 D1 DE60332975 D1 DE 60332975D1 DE 60332975 T DE60332975 T DE 60332975T DE 60332975 T DE60332975 T DE 60332975T DE 60332975 D1 DE60332975 D1 DE 60332975D1
Authority
DE
Germany
Prior art keywords
ranolazine
eads
depolarization
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332975T
Other languages
German (de)
English (en)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Application granted granted Critical
Publication of DE60332975D1 publication Critical patent/DE60332975D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60332975T 2002-04-04 2003-04-04 Verwendung von Ranolazin zur Herstellung eines Medikaments zur Behandlung von frühen Nachdepolarisationen (EADs) Expired - Lifetime DE60332975D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
DE60332975D1 true DE60332975D1 (de) 2010-07-22

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60332975T Expired - Lifetime DE60332975D1 (de) 2002-04-04 2003-04-04 Verwendung von Ranolazin zur Herstellung eines Medikaments zur Behandlung von frühen Nachdepolarisationen (EADs)
DE60321550T Expired - Lifetime DE60321550D1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60321550T Expired - Lifetime DE60321550D1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien

Country Status (19)

Country Link
US (2) US20030220344A1 (enExample)
EP (3) EP1490066B1 (enExample)
JP (1) JP4608217B2 (enExample)
KR (2) KR20040099395A (enExample)
CN (2) CN100548300C (enExample)
AT (2) ATE397932T1 (enExample)
AU (3) AU2003230810B2 (enExample)
CA (1) CA2481192C (enExample)
CY (1) CY1110400T1 (enExample)
DE (2) DE60332975D1 (enExample)
DK (2) DK1930007T3 (enExample)
ES (2) ES2345573T3 (enExample)
IL (1) IL197406A0 (enExample)
MX (1) MXPA04009637A (enExample)
NO (1) NO330953B1 (enExample)
NZ (1) NZ535610A (enExample)
PT (2) PT1930007E (enExample)
SI (2) SI1930007T1 (enExample)
WO (1) WO2003086401A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP2007514769A (ja) * 2003-12-18 2007-06-07 シーブイ・セラピューティクス・インコーポレイテッド １−アルカン−２−オール置換ピペラジンおよびピペリジン化合物
US20060111361A1 (en) * 2004-11-09 2006-05-25 Brent Blackburn Method of reversing left ventricle remodeling
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
US20060264458A1 (en) * 2005-05-03 2006-11-23 Jie Du Quinine dosage forms and methods of use thereof
CA2670651A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008101002A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
KR20110013348A (ko) * 2008-02-06 2011-02-09 길리애드 사이언시즈, 인코포레이티드 통증 치료를 위한 라놀라진의 용도
US20100056536A1 (en) * 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US20150148352A1 (en) * 2012-08-14 2015-05-28 Cellixbio Private Limited Compositions and methods for the treatment angina and cardiovascular conditions
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
HK1219893A1 (zh) 2013-08-01 2017-04-21 吉利德科学公司 治療長qt綜合征的化合物和方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
KR101617683B1 (ko) * 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN116808039A (zh) * 2023-03-27 2023-09-29 河南中医药大学第一附属医院 青藤碱在制备钾离子、钠离子通道抑制剂中的应用
WO2025010429A1 (en) * 2023-07-06 2025-01-09 The General Hospital Corporation Method and apparatus for evaluating cardiac function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE69033967T2 (de) * 1989-06-23 2002-12-19 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
EP0720605B1 (en) * 1993-09-24 2001-12-19 University Of British Columbia Aminocyclohexylesters and uses thereof
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2004505886A (ja) * 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
KR100518046B1 (ko) * 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
ES2345573T3 (es) 2010-09-27
KR20100119804A (ko) 2010-11-10
IL197406A0 (en) 2011-07-31
ATE470445T1 (de) 2010-06-15
DK1490066T3 (da) 2008-10-13
CA2481192C (en) 2012-07-03
SI1930007T1 (sl) 2010-08-31
JP2005528393A (ja) 2005-09-22
CY1110400T1 (el) 2015-04-29
SI1490066T1 (sl) 2008-10-31
US20030220344A1 (en) 2003-11-27
US20100004255A1 (en) 2010-01-07
CN100548300C (zh) 2009-10-14
PT1490066E (pt) 2008-07-22
CN101843619A (zh) 2010-09-29
KR20040099395A (ko) 2004-11-26
AU2003230810B2 (en) 2009-02-26
ATE397932T1 (de) 2008-07-15
ES2304507T3 (es) 2008-10-16
EP1930007A1 (en) 2008-06-11
AU2009201065B2 (en) 2011-07-21
AU2009201065A1 (en) 2009-04-09
CA2481192A1 (en) 2003-10-23
AU2003230810A1 (en) 2003-10-27
HK1120390A1 (en) 2009-04-03
CN1646127A (zh) 2005-07-27
PT1930007E (pt) 2010-08-17
EP1490066B1 (en) 2008-06-11
DK1930007T3 (da) 2010-08-30
AU2011202135A1 (en) 2011-05-26
DE60321550D1 (de) 2008-07-24
NO330953B1 (no) 2011-08-22
JP4608217B2 (ja) 2011-01-12
MXPA04009637A (es) 2005-07-14
NO20044783L (no) 2004-11-03
EP2198866A1 (en) 2010-06-23
EP1490066A1 (en) 2004-12-29
EP1930007B1 (en) 2010-06-09
WO2003086401A1 (en) 2003-10-23
NZ535610A (en) 2006-05-26

Similar Documents

Publication Publication Date Title
DE60332975D1 (de) Verwendung von Ranolazin zur Herstellung eines Medikaments zur Behandlung von frühen Nachdepolarisationen (EADs)
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
ATE517658T1 (de) Arrythmie-klassifizierung und therapiewahl
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
WO2003102016A3 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
NO20011244D0 (no) Behandling av multippelt myelom samt myelom-indusert benresorpsjon ved anvendelse av integrin-antagonister
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE50213170D1 (de) Verwendung eines Mittel zur Therapie der Herzhypertrophie
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
WO2004044144A3 (en) Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
AU4584100A (en) Morphinoid compounds
DE602004016292D1 (de) Verwendung einer zusammensetzung mit vitamin k1-oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
DE60202446T8 (de) Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen
DE60009069D1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
ATE497784T1 (de) Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE127118T1 (de) 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia.
ATE376914T1 (de) Verwendung einer wässrigen lösung mit einem oder mehreren bifluoriden zur verbesserung des trocknungsprozesses von frischholz

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1930007

Country of ref document: EP

Representative=s name: VOLKER VOSSIUS, DE